Detecting and preventing complications in pregnancy
- QuidelOrtho receives Canadian approval for angiogenic imbalance test
- Health Canada approves Triage PLGF test for laboratory use
- Test detects placental growth factor in maternal plasma specimens
- Angiogenic imbalance can lead to maternal and fetal complications
- Pre-eclampsia affects up to 5% of pregnancies in Canada
QuidelOrtho, a San Diego-based in vitro diagnostics company, has received approval from Canadian regulators for its test to detect angiogenic imbalance. The test, known as Triage PLGF, is a fluorescence immunoassay used to quantitatively determine placental growth factor in maternal plasma specimens. Angiogenic imbalance can lead to complications in both the mother and fetus during pregnancy, including the development of pre-eclampsia, a high-blood-pressure condition that affects up to 5% of pregnancies in Canada.
Factuality Level: 8
Factuality Justification: The article provides factual information about QuidelOrtho receiving approval for its test from Canadian regulators, the details of the test, and the potential complications related to angiogenic imbalance in pregnancy. The information presented is straightforward and does not contain any obvious biases, inaccuracies, or sensationalism.
Noise Level: 3
Noise Justification: The article provides relevant information about QuidelOrtho receiving approval for its test in Canada, the purpose of the test, and the potential complications it can help detect. The article stays on topic and does not contain irrelevant or misleading information. It supports its claims with details about the test and its implications. However, it could benefit from more in-depth analysis or insights into the broader implications of this approval.
Financial Relevance: Yes
Financial Markets Impacted: No
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article pertains to a medical test approval in Canada and does not mention any financial markets or extreme events.
Public Companies: QuidelOrtho (Not available)
Key People: Ben Glickman (Not available)
Reported publicly:
www.marketwatch.com 
